<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161313</url>
  </required_header>
  <id_info>
    <org_study_id>hdenizkulli2</org_study_id>
    <nct_id>NCT04161313</nct_id>
  </id_info>
  <brief_title>Respiratory Function, Exercise Capacity and Peripheral Muscle Strength Among Patients With CF, PCD and Healthy Children</brief_title>
  <official_title>Comparison of Respiratory Function, Exercise Capacity and Peripheral Muscle Strength Among Patients With Cystic Fibrosis, Primary Ciliary Dyskinesia and Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare pulmonary function, respiratory muscle strength, exercise
      capacity and peripheral muscle strength of patients with CF, PCD and healthy childrens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impaired airway clearence and pulmonary functions, exercise intolerance, low physical
      activity level and decreased peripheral muscle strength make physiotherapy approaches
      important in the management of CF and PCD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Six-minute walk test distance</measure>
    <time_frame>15 minutes</time_frame>
    <description>Distance walked in six minutes will be recorded in meters. Test will be conducted according to the guideline of American Thoracic Society (ATS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>5 minutes</time_frame>
    <description>FVC will be measured using basic spirometry and expressed as the percentage of the predicted value according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>5 minutes</time_frame>
    <description>FEV1 will be measured using basic spirometry and expressed as the percentage of the predicted value according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF)</measure>
    <time_frame>5 minutes</time_frame>
    <description>PEF will be measured using basic spirometry and expressed as the percentage of the predicted value according to the guideline of European Respiratory Society (ERS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M. Quadriceps strength</measure>
    <time_frame>5 minutes</time_frame>
    <description>Isometric M. Quadriceps strength (kg) will be measured using electronic hand held dynamometer in sitting position.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">76</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cystic fibrosis</arm_group_label>
    <description>children with cystic fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>primary ciliary dyskinesia</arm_group_label>
    <description>children with primary ciliary dyskinesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>Age-matched healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of functional capacity</intervention_name>
    <description>Functional capacity of participants will be measured with six-minute walk test.</description>
    <arm_group_label>Cystic fibrosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>primary ciliary dyskinesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pulmonary function test</intervention_name>
    <description>It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75</description>
    <arm_group_label>Cystic fibrosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>primary ciliary dyskinesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional capacity</intervention_name>
    <description>Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test</description>
    <arm_group_label>Cystic fibrosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>primary ciliary dyskinesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral muscle strength</intervention_name>
    <description>Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.</description>
    <arm_group_label>Cystic fibrosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>primary ciliary dyskinesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Respiratory muscle strength</intervention_name>
    <description>Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.</description>
    <arm_group_label>Cystic fibrosis</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>primary ciliary dyskinesia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children diagnosed with cystic fibrosis and primary ciliary dyskinesia and age matched
        healthy volunteers who do not have any diagnosed chronic diseases
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cystic fibrosis or primary ciliary dyskinesia

        Exclusion Criteria:

          -  Hospitalization history in past month

          -  Diagnosis of other chronic pediatric diseases which may impair exercise tolerance such
             as cerebral palsy or neuromuscular disease

          -  Candidates for lung transplantation or history of lung transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilal Denizoglu Kulli, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bezmialem Vakif University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bezmialem Vakıf University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bezmialem Vakif University</investigator_affiliation>
    <investigator_full_name>Hilal Denizoğlu Külli</investigator_full_name>
    <investigator_title>Lecturer in Department of Physiotheray and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>respiratory functions</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>muscle strength</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

